These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 21266922)

  • 1. Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing.
    Rekhtman N; Brandt SM; Sigel CS; Friedlander MA; Riely GJ; Travis WD; Zakowski MF; Moreira AL
    J Thorac Oncol; 2011 Mar; 6(3):451-8. PubMed ID: 21266922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subtyping of non-small cell lung carcinoma: a comparison of small biopsy and cytology specimens.
    Sigel CS; Moreira AL; Travis WD; Zakowski MF; Thornton RH; Riely GJ; Rekhtman N
    J Thorac Oncol; 2011 Nov; 6(11):1849-56. PubMed ID: 21841504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for EGFR and KRAS mutations in non-small cell lung carcinomas using DNA extraction by hydrothermal pressure coupled with PCR-based direct sequencing.
    Liu Y; Wu BQ; Zhong HH; Hui P; Fang WG
    Int J Clin Exp Pathol; 2013; 6(9):1880-9. PubMed ID: 24040454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening for EGFR and KRAS mutations in endobronchial ultrasound derived transbronchial needle aspirates in non-small cell lung cancer using COLD-PCR.
    Santis G; Angell R; Nickless G; Quinn A; Herbert A; Cane P; Spicer J; Breen R; McLean E; Tobal K
    PLoS One; 2011; 6(9):e25191. PubMed ID: 21949883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
    Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
    J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Non-small cell lung cancer. Subtyping and predictive molecular marker investigations in cytology].
    Savic S; Bihl MP; Bubendorf L
    Pathologe; 2012 Jul; 33(4):301-7. PubMed ID: 22711372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Relationship between EGFR and KRAS mutations and prognosis in Chinese patients with non-small cell lung cancer: a mutation analysis with real-time polymerase chain reaction using scorpion amplification refractory mutation system].
    Gao J; Chen JQ; Zhang L; Liang ZY
    Zhonghua Bing Li Xue Za Zhi; 2012 Oct; 41(10):652-6. PubMed ID: 23302304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and EGFR [corrected] mutation.
    Nunez MI; Behrens C; Woods DM; Lin H; Suraokar M; Kadara H; Hofstetter W; Kalhor N; Lee JJ; Franklin W; Stewart DJ; Wistuba II
    J Thorac Oncol; 2012 May; 7(5):833-40. PubMed ID: 22729036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spectrum of somatic EGFR, KRAS, BRAF, PTEN mutations and TTF-1 expression in Brazilian lung cancer patients.
    Carneiro JG; Couto PG; Bastos-Rodrigues L; Bicalho MA; Vidigal PV; Vilhena A; Amaral NF; Bale AE; Friedman E; De Marco L
    Genet Res (Camb); 2014; 96():e002. PubMed ID: 24594201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations.
    Rekhtman N; Paik PK; Arcila ME; Tafe LJ; Oxnard GR; Moreira AL; Travis WD; Zakowski MF; Kris MG; Ladanyi M
    Clin Cancer Res; 2012 Feb; 18(4):1167-76. PubMed ID: 22228640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A brief retrospective report on the feasibility of epidermal growth factor receptor and KRAS mutation analysis in transesophageal ultrasound- and endobronchial ultrasound-guided fine needle cytological aspirates.
    Schuurbiers OC; Looijen-Salamon MG; Ligtenberg MJ; van der Heijden HF
    J Thorac Oncol; 2010 Oct; 5(10):1664-7. PubMed ID: 20871266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
    Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
    J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adequacy of lymph node transbronchial needle aspirates using convex probe endobronchial ultrasound for multiple tumor genotyping techniques in non-small-cell lung cancer.
    Folch E; Yamaguchi N; VanderLaan PA; Kocher ON; Boucher DH; Goldstein MA; Huberman MS; Kent MS; Gangadharan SP; Costa DB; Majid A
    J Thorac Oncol; 2013 Nov; 8(11):1438-1444. PubMed ID: 24128714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Napsin A/p40 antibody cocktail for subtyping non-small cell lung carcinoma on cytology and small biopsy specimens.
    Nishino M; Hoang MP; Della Pelle P; Morales-Oyarvide V; Huynh TG; Mark EJ; Mino-Kenudson M
    Cancer Cytopathol; 2016 Jul; 124(7):472-84. PubMed ID: 27412420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Feasibility of assessing EGFR mutation and others using samples obtained by EBUS transbronchial needle aspiration].
    Boulanger S; Delattre C; Descarpentries C; Escande F; Bouchindhomme B; Copin MC; Dhalluin X; Scherpereel A; Ramon PP; Cortot A; Fournier C
    Rev Mal Respir; 2013 May; 30(5):351-6. PubMed ID: 23746811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of EML4-ALK fusion genes in non-small cell lung cancer patients with clinical features associated with EGFR mutations.
    Shaozhang Z; Xiaomei L; Aiping Z; Jianbo H; Xiangqun S; Qitao Y
    Genes Chromosomes Cancer; 2012 Oct; 51(10):925-32. PubMed ID: 22736493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis.
    Nicholson AG; Gonzalez D; Shah P; Pynegar MJ; Deshmukh M; Rice A; Popat S
    J Thorac Oncol; 2010 Apr; 5(4):436-41. PubMed ID: 20068475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR and KRAS mutation analysis in cytologic samples of lung adenocarcinoma enabled by laser capture microdissection.
    Chowdhuri SR; Xi L; Pham TH; Hanson J; Rodriguez-Canales J; Berman A; Rajan A; Giaccone G; Emmert-Buck M; Raffeld M; Filie AC
    Mod Pathol; 2012 Apr; 25(4):548-55. PubMed ID: 22157931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genotyping non-small cell lung cancer (NSCLC) in Latin America.
    Arrieta O; Cardona AF; Federico Bramuglia G; Gallo A; Campos-Parra AD; Serrano S; Castro M; Avilés A; Amorin E; Kirchuk R; Cuello M; Borbolla J; Riemersma O; Becerra H; Rosell R;
    J Thorac Oncol; 2011 Nov; 6(11):1955-9. PubMed ID: 22005474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anaplastic lymphoma kinase gene rearrangements in cytological samples of non-small cell lung cancer: comparison with histological assessment.
    Proietti A; Alì G; Pelliccioni S; Lupi C; Sensi E; Boldrini L; Servadio A; Chella A; Ribechini A; Cappuzzo F; Miccoli M; Fontanini G
    Cancer Cytopathol; 2014 Jun; 122(6):445-53. PubMed ID: 24648382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.